CBC and metabolic panel
Can reveal general health changes, but cannot screen for or diagnose lung cancer.
LDCT-first screening guide
Blood Test for Lung Cancer
Routine blood work cannot find lung cancer. This guide explains the proven role of low-dose CT and where a multi-cancer blood test may add information without replacing it.
Start with the direct answerClinical review status
Pending physician review. A named MD has not yet been supplied; no medical reviewer is represented in the page schema.
The direct answer
Can a Blood Test Detect Lung Cancer?
Standard blood tests such as a CBC cannot detect lung cancer. A newer category—multi-cancer early detection (MCED) tests—can identify a cancer-associated signal using cell-free DNA methylation patterns. Galleri® screens for a signal shared by more than 50 cancer types, including lung; it is under FDA review and does not replace low-dose CT screening.
Biomarker testing
Looks for alterations such as EGFR, ALK and KRAS to help guide therapy in a person already diagnosed.
Early-detection screening
Galleri analyzes cfDNA methylation patterns in people without a known cancer diagnosis.
The proven screening pathway
How Is Lung Cancer Currently Screened For?
The USPSTF recommends annual low-dose CT (LDCT) screening for adults ages 50–80 who have at least a 20 pack-year smoking history and currently smoke or quit within the past 15 years. LDCT is the guideline-recommended standard for eligible high-risk adults.
LDCT uses low-dose X-rays to find lung nodules. Large trials, including NLST and NELSON, showed that screening an eligible high-risk population can reduce lung cancer mortality. An abnormal scan may lead to repeat imaging, PET-CT or biopsy.
Screening is for people without symptoms. Coughing up blood, a persistent or changing cough, unexplained weight loss, chest pain or shortness of breath calls for prompt clinical evaluation, not a screening blood test.
A narrow eligibility pathway
Why Most Americans Don't Get Lung Cancer Screening
LDCT eligibility depends on both age and a specific smoking history. Never-smokers, lighter smokers and people who quit more than 15 years ago generally fall outside the current USPSTF recommendation, while some eligible adults do not complete annual screening.
Eligibility is not the same as diagnosis
Anyone with concerning symptoms or an abnormal finding needs clinical evaluation, whether or not they qualify for routine LDCT screening.
One blood draw, a different signal
What Is the Galleri Multi-Cancer Blood Test?
Galleri is an MCED blood test that analyzes cell-free DNA methylation patterns. It screens for a shared cancer-associated signal across more than 50 cancer types—including lung—and predicts a Cancer Signal Origin to help guide follow-up.
Methylation is an epigenetic pattern that affects how DNA is read. Galleri uses these patterns rather than looking primarily for the tumor mutations used in treatment-selection liquid biopsies. It does not diagnose cancer.
Galleri is recommended for adults with elevated cancer risk, such as those 50 or older, and requires a prescription. Human Longevity sells the GRAIL test for $798. It is not a lung-specific test. See Galleri cost and coverage.
Prospective evidence first
How Well Does Galleri Detect Lung Cancer?
Lung is in GRAIL's pre-specified group of 12 cancers, but verified prospective lung-only performance is not presented here. Group results should not be applied to one cancer.
69.8%Episode sensitivity for the pre-specified 12-cancer group
39.3%Episode sensitivity across all cancers
99.6%Specificity across all cancers
These PATHFINDER 2 full results were reported for 35,878 adults age 50 or older in May 2026. They are aggregate figures, not lung-specific sensitivity. The study also reported overall Cancer Signal Origin accuracy of 91.3%.
NHS-Galleri results were mixed: its primary endpoint was not met, while Stage IV diagnoses declined in later screening rounds. A “No Cancer Signal Detected” result does not rule out lung cancer.
Different tools, different jobs
Galleri and LDCT — Complementary, Not Competing
Galleri does not replace LDCT. For adults who qualify, annual LDCT remains the guideline-recommended and best-established route for finding lung cancer early. Galleri adds a multi-cancer signal from a blood draw.
| Feature | LDCT screening | Galleri MCED test |
|---|---|---|
| What it detects | Lung nodules through imaging | A cancer-associated signal through cfDNA methylation |
| Who qualifies | Adults 50–80 with a 20+ pack-year history who currently smoke or quit within 15 years | Rx required; recommended for adults with elevated cancer risk, such as those 50 or older |
| How often | Annually | As recommended by the prescribing clinician |
| Role | Guideline-recommended lung cancer screening for eligible adults | Supplemental multi-cancer screening; not a replacement for LDCT |
| Cancers screened | Lung only | A signal shared by more than 50 cancer types, including lung |
| Cost and coverage | Often covered for eligible adults | $798 through HLI; not covered by Medicare |
| Requires | CT scanner and radiology interpretation | Blood draw and laboratory analysis |
These tools were studied in different populations and should not be treated as a head-to-head comparison. A positive Galleri result requires diagnostic workup; a negative result cannot rule out cancer.
Do not confuse two kinds of liquid biopsy
Biomarker Testing vs Early Detection — What's the Difference?
Biomarker testing for EGFR, ALK, KRAS, ROS1, BRAF, RET, MET, HER2, NTRK or PD-L1 is used after a lung cancer diagnosis to help select treatment. Early-detection tests such as Galleri are used before a known diagnosis to screen for a cancer-associated signal.
A treatment-selection liquid biopsy usually looks for tumor-derived mutations in circulating tumor DNA (ctDNA). The result may help match non-small cell lung cancer (NSCLC) with targeted treatment.
Galleri analyzes methylation patterns in cell-free DNA (cfDNA). It is not a companion diagnostic, does not identify a therapy, and does not distinguish NSCLC from small cell lung cancer (SCLC).
Routine bloodwork has a supporting role
What Blood Tests Can Tell You About Lung Cancer
A CBC measures white blood cells, red blood cells and platelets. It can identify anemia, infection or other health changes, but it cannot screen for or diagnose lung cancer. Tumor markers are not reliable enough for routine lung cancer screening.
If lung cancer is suspected, clinicians usually begin with chest imaging. PET-CT can help assess spread; bronchoscopy, needle biopsy or another tissue biopsy confirms the diagnosis and identifies NSCLC or SCLC. Pathology then establishes type and stage.
Sputum cytology may be useful in selected situations but is not a general screening test. Molecular profiling follows diagnosis when it may guide treatment. An unusual white blood cell count alone does not establish lung cancer.
Clear answers
Frequently Asked Questions
Is there a blood test that can detect lung cancer early?
Multi-cancer early detection tests such as Galleri screen for a cancer signal, including signals associated with lung cancer, using cell-free DNA methylation analysis. Galleri is not a lung-cancer-specific test, is under FDA review, and does not replace low-dose CT screening for eligible adults.
Does lung cancer show up on routine blood work?
No. A standard complete blood count or metabolic panel cannot detect lung cancer. Advanced cancer can sometimes cause nonspecific changes such as anemia or elevated calcium, but those findings have many possible causes.
What is the 5-finger test for lung cancer?
It is not a medically recognized diagnostic test. Informal awareness checks cannot diagnose or screen for lung cancer. New or persistent symptoms need clinical evaluation.
What is the newest blood test for lung cancer?
Galleri is a multi-cancer blood test studied prospectively in PATHFINDER 2 and NHS-Galleri. It analyzes cell-free DNA methylation patterns from a blood draw and is under FDA review. Other blood-based approaches remain in development. LDCT remains the guideline-recommended lung screening method.
Can a non-smoker get lung cancer screening?
People without the smoking history specified by USPSTF generally do not qualify for guideline-recommended LDCT screening. Galleri requires a prescription and is recommended for adults with elevated cancer risk, such as those 50 or older, but it is not a lung-cancer screen and does not replace LDCT where LDCT applies.
Inherited risk is a separate question
Where Whole Genome Sequencing Fits
Whole genome sequencing does not detect existing lung cancer, does not replace LDCT or Galleri, and cannot make someone eligible for LDCT. Smoking history remains the dominant clinical risk factor.
For a strong family history, a clinician can help decide whether genetic counseling is appropriate. See what the $599 genome service includes.
Sources and Evidence Notes
Key sources: USPSTF lung cancer screening recommendation (2021); Jonas et al., JAMA (2021, LDCT evidence review); National Lung Screening Trial, New England Journal of Medicine (2011); de Koning et al., New England Journal of Medicine (2020, NELSON); Klein et al., Annals of Oncology (2021, case-control MCED validation); GRAIL PATHFINDER 2 full-results release (May 31, 2026); GRAIL NHS-Galleri release (2026); Galleri HCP performance page; and FDA advisory committee materials (September 23, 2026). Study percentages describe populations, not one person.